Skip to main content
OpenTrials
Completed

NCT Number: NCT03092999

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For all subjects:

  • The informed consent must be signed before any study specific tests or procedures are done
  • White/Caucasian men and women aged between 18 to 79 years (inclusive )
  • Body mass index (BMI): 18 to 34 kg/m2 (both inclusive)
  • Ability to understand and follow study-related instructions
  • Women and men of reproductive potential must agree to use adequate contraception when sexually active. This applies for the time period between signing of the informed consent form and three months after administration of study drug. Subjects must agree to use two non-hormonal methods for contraception simultaneously (e.g. condom or diaphragm, plus spermicide) throughout the study when sexually active.

This is not required if safe contraception is achieved by a permanent method, such as hysterectomy, bilateral fallopian tube ligation or vasectomy.

For subjects with hepatic impairment:

  • Subjects with documented liver cirrhosis confirmed by histopathology, laparoscopy, fibroscan, or ultrasound
  • Subjects with hepatic impairment (Child-Pugh A or B)
  • Subjects with stable liver disease, i.e. same Child-Pugh class in the last 2 months

Exclusion criteria

  • Any relevant disease within 4 weeks prior to study drug administration requiring medical treatment
  • Known severe allergies, non-allergic drug reactions, or multiple drug allergies
  • Use containing sex hormones within 4 weeks to six months before first study drug administration
  • Use of CYP3A4 and P-glycoprotein inhibitors or inducers
  • Use of drugs which may affect absorption
  • Major change of medication <2 weeks prior study drug administration
  • Deviations from normal range in physical examination, gynecological examination, clinical chemistry, hematology, or urinalysis considered to be relevant by the investigator
  • Any criteria which, in the opinion of the investigator, make study participation unadvisable for scientific, compliance, safety, or medical reasons

Treatment and study plan

Vilaprisan (BAY1002670)

Drug

2 mg tablet, single dose, oral administration

Primary outcomes

  1. Area under the concentration vs. time curve in plasma from zero to infinity (AUCu) (unbound)

    Time frame: At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days

    Exposure of Vilaprisan in plasma following a single dose administration

  2. Maximum observed (unbound) drug concentration (Cmax,u)

    Time frame: At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days

    Maximum observed (unbound) drug concentration (Cmax,u) in measured matrix after a single dose administration

Secondary outcomes

  1. Frequency of Treatment Emergent Adverse Events

    Time frame: Up to 20 days

    Frequency of Treatment Emergent Adverse Events as a measure of safety and tolerability

  2. Severity of Treatment Emergent Adverse Events

    Time frame: Up to 20 days

    The intensity of an AE is classified according to the following categories:

    • Mild
    • Moderate
    • Severe
  3. Changes in blood laboratory parameters

    Time frame: Up to 20 days

    Changes in blood laboratory parameters including hematology, clotting status, serum chemistry

  4. Changes in urine laboratory parameters

    Time frame: Up to 20 days

    Changes in urine laboratory parameters including urine analysis, urine pregnancy tests

  5. Changes in Vital Signs

    Time frame: Up to 20 days

    Changes in Vital Signs, including blood pressure, pulse, body temperature

  6. Changes in Electrocardiogram (ECG)

    Time frame: Up to 20 days

    ECG (12-lead) after ≥10 minutes supine rest

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Investigation of Pharmacokinetics, Safety, and Tolerability of Vilaprisan (BAY1002670) in Subjects With Hepatic Impairment (Classified as Child-Pugh A or B) Compared to Sex, Age, and Weight-matched Healthy Subjects Following a Single Oral Dose

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Mar 28, 2017
Registry last updated
Aug 18, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.